Optimal glycemic control during the first years after a latent autoimmune diabetes of adulthood diagnosis could prevent people’s microvascular complication risk from equaling that seen in those with type 2 diabetes, shows an analysis of the UKPDS.
The benefits and harms of intensive glucose control in people with type 2 diabetes may depend on which form of haptoglobin they have, shows an analysis of the ACCORD trial.
Initiating insulin glargine 300 U/mL could help half of those patients whose type 2 diabetes is inadequately controlled with oral antidiabetic medication to achieve their personal glycemic target within a year, real-world data suggest.
Gaining weight after stopping smoking attenuates the cardiovascular disease benefits of quitting in people with type 2 diabetes, but does not appear to lessen its positive effect on mortality, shows research.
People with type 2 diabetes who are treated with sodium-glucose cotransporter 2 inhibitors are less likely to develop gout than those given glucagon-like peptide-1 receptor agonists, researchers report.
Patients with type 2 diabetes who are treated with SGLT2 inhibitors in routine clinical practice have a lower rate of kidney function decline and a reduced risk for adverse renal events compared with those given other glucose-lowering drugs, researchers report.
A large survey has uncovered a number of issues that particularly frustrate people with diabetes during their interactions with their healthcare providers.
People with type 2 diabetes and reduced kidney function in the absence of albuminuria have an increased risk for mortality and major adverse cardiovascular events, despite a low risk for end-stage renal disease, research shows.
Swedish research suggests that determining type 2 diabetes duration prior to bariatric surgery could help prioritize those patients most likely to achieve diabetes remission.
People who are trying to maintain weight loss with the help of electronic health records-based tracking tools do significantly better if they are given access to an online coach, shows a randomized trial.
People with obesity and type 2 diabetes who undergo gastric bypass surgery have higher rates of diabetes remission after 1 year than those undergoing sleeve gastrectomy, indicate findings from the Oseberg trial.
Adding the DPP-4 inhibitor sitagliptin to first-line metformin therapy may delay the need for exogenous insulin among people with type 2 diabetes, researchers report.
Fasting C-peptide levels can “provide valuable information” to guide the approach to titrating basal insulin in new users with type 2 diabetes, say researchers.
Is this increasingly popular weight management tactic an option for your patients with type 2 diabetes? Primary care physician Jay Shubrook and Jamie Katuna explain in this illustrative case study [read more].
Known sex differences among younger patients with type 2 diabetes persist among those aged 90 years and older, particularly optimal use of cardiovascular preventive therapies which is significantly less likely among women than men, Spanish research shows.
What's new in the 2019 update to the ADA guidelines on nutrition therapy for adults with diabetes or prediabetes? Diabetes Educator Amy Hess Fischl explains [read more].
People with type 2 diabetes and obesity who undergo metabolic surgery have a significantly lower risk for major adverse cardiovascular events than those who do not receive surgery, observational study data show.
Nurse and Diabetes Educator Lori Berard highlights the advantages of “concentrated” insulins and outlines her recommendations for getting titration right for patients.
WATCH | Katherine Tuttle and Jay Shubrook reconvene to discuss what the landmark findings from recent renal outcomes trials mean for clinical practice (16:51).
Diagnosis and management of prediabetes: a consensus of GCC countries
Guidance based on outcomes of an advisory board of diabetes experts, for healthcare professionals addressing the diagnosis and treatment of prediabetes.
This interactive roadmap is intended for healthcare professionals practicing in Saudi Arabia, Kuwait, the United Arab Emirates, Qatar, Bahrain, and Oman.
Funding for this roadmap was provided by Merck Serono Middle East FZ-LLC
These slide sets summarize the results of randomized controlled trials investigating the use of flash glucose-sensing technology in patients with diabetes.
Funded by an educational grant from Abbott Diabetes Care
An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.
A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.
Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.
Themed collections
Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.
Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.
